
Haoran Zha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3047642/publications.pdf Version: 2024-02-01



ΗλΟΡΛΝ ΖΗΛ

#	Article	IF	CITATIONS
1	Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Cancer Immunology Research, 2019, 7, 193-207.	1.6	64
2	Blocking C5aR signaling promotes the anti-tumor efficacy of PD-1/PD-L1 blockade. Oncolmmunology, 2017, 6, e1349587.	2.1	56
3	Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer. Frontiers in Immunology, 2020, 11, 582657.	2.2	49
4	Stroma-derived Fibrinogen-like Protein 2 Activates Cancer-associated Fibroblasts to Promote Tumor Growth in Lung Cancer. International Journal of Biological Sciences, 2017, 13, 804-814.	2.6	35
5	C3a-C3aR signaling promotes breast cancer lung metastasis via modulating carcinoma associated fibroblasts. Journal of Experimental and Clinical Cancer Research, 2020, 39, 11.	3.5	35
6	Control of Intestinal Inflammation, Colitis-Associated Tumorigenesis, and Macrophage Polarization by Fibrinogen-Like Protein 2. Frontiers in Immunology, 2018, 9, 87.	2.2	30
7	Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells. International Journal of Molecular Sciences, 2017, 18, 22.	1.8	29
8	Systemic Immune-Inflammation Index and Changes of Neutrophil-Lymphocyte Ratio as Prognostic Biomarkers for Patients With Pancreatic Cancer Treated With Immune Checkpoint Blockade. Frontiers in Oncology, 2021, 11, 585271.	1.3	27
9	Centromere protein U expression promotes non-small-cell lung cancer cell proliferation through FOXM1 and predicts poor survival. Cancer Management and Research, 2018, Volume 10, 6971-6984.	0.9	23
10	Non-canonical PD-1 signaling in cancer and its potential implications in clinic. , 2021, 9, e001230.		15

2